If You Invested in Xebra Brands (XBRAF)

Xebra Brands Ltd. (OTC: XBRAF) is a cannabis-focused company that appears in the Drug Manufacturers – Specialty & Generic industry and the healthcare sector on many market classification platforms. According to its public disclosures, Xebra positions itself as a Canadian cannabis company with international reach, concentrating on the development and commercialization of cannabis‑derived wellness and consumer products.

In multiple news releases, Xebra describes itself as an international cannabis cultivation and product company with global brands and intellectual property. Its stated focus areas include beverages, wellness and leisure. The company has highlighted its role in the Mexican cannabis sector, noting that it received authorization from the Mexican health regulatory agency COFEPRIS to import, cultivate, manufacture and sell cannabis with less than 1% THC in Mexico. Xebra has characterized this as the first such full authorization granted to a corporation by COFEPRIS.

Xebra also discloses activities in Canada and the United States. In Canada, the company has stated that it retails Vicious Citrus THC/CBN lemonades. In the United States, Xebra has described a strategy centered on its ELEMENTS™ CBD product line. Through manufacturing and distribution agreements, including with NF Skin and its logistics division RT Fulfillment, Xebra reports that it is working to commercialize ELEMENTS™ branded tinctures, gummies, topicals and wellness supplements for e‑commerce and retail channels.

Across its communications, Xebra emphasizes cannabis‑derived wellness products and branded consumer offerings. It notes that it is actively expanding the ELEMENTS™ product line through strategic partnerships in North America, and that it aims to build trusted brands in North American and Mexican markets. The company also references its global brands and intellectual property as part of its business profile.

Xebra’s public updates provide insight into its corporate and capital markets status. The company’s shares trade on the Canadian Securities Exchange under the symbol XBRA, on the OTC market under XBRAF, and on the Frankfurt Stock Exchange under 9YC or 9YC0, depending on the specific release. In several 2025 news releases, Xebra reports liquidity constraints and delays in filing its audited annual financial statements and related management discussion and analysis for the fiscal year ended February 28, 2025. These delays led to the application for, and granting of, a management cease trade order (MCTO) by the British Columbia Securities Commission, and later to a failure‑to‑file cease trade order (CTO) that suspended trading in its securities in Canadian jurisdictions until required filings are made.

The company has also announced a share consolidation of its common shares on a ten‑for‑one basis, subject to regulatory approval and the status of the CTO. Xebra has explained that fractional shares resulting from the consolidation will be rounded according to specified thresholds, and that its warrants and options will be adjusted on the same basis. It has described the mechanics of exchanging pre‑consolidation share certificates for post‑consolidation certificates through its transfer agent for registered shareholders, while indicating that non‑registered shareholders are not required to take action for the consolidation to be reflected in their accounts.

In addition to corporate actions, Xebra has disclosed financing arrangements and changes in management. It reported entering into a loan agreement with an existing shareholder and co‑founder to provide funds for working capital and to support completion of its audit and annual filings. The company has also announced management changes, including resignations of certain officers and directors and the appointment of its chief executive officer as interim chief financial officer until a replacement is identified.

From a regulatory and compliance perspective, Xebra’s releases describe its interaction with Canadian securities regulators, including the application for an MCTO under National Policy 12‑203 and the issuance of a CTO under Multilateral Instrument 11‑103 for failure to file required continuous disclosure documents. The company has stated that it intends to comply with alternative information guidelines by issuing bi‑weekly default status reports while in default of filing requirements.

Business focus and product lines

Based on its public statements, Xebra’s business focus includes:

• Development and commercialization of cannabis‑derived wellness products.
• International cannabis cultivation and product development, with a particular emphasis on Mexico and North America.
• Branded beverages, wellness and leisure products, including Vicious Citrus THC/CBN lemonades in Canada.
• ELEMENTS™ CBD product line, including tinctures, gummies, topicals and wellness supplements for the U.S. market, supported by manufacturing and logistics partners.

The company has described its Mexican operations as federally licensed, and has highlighted its COFEPRIS authorization as a key element of its positioning in that market. It has also referenced strategic partnerships as a means to expand its product distribution and commercialization in North America.

Trading status and risk context

Xebra’s disclosures indicate that investors should be aware of regulatory and filing‑related developments. The company has publicly acknowledged liquidity constraints, delays in financial reporting, and the resulting MCTO and CTO that affect trading in its securities, particularly on the Canadian Securities Exchange. It has also reported that its OTC listing was moved from the OTCQB Market to the OTC Pink Open Market, which it notes provides a regulated platform for transparent trading but reflects a different tier of the U.S. over‑the‑counter market.

These factors, along with the company’s reliance on regulatory authorizations in Mexico and other jurisdictions, and the general risks associated with cannabis cultivation, product development, and regulatory compliance, are discussed in Xebra’s forward‑looking statements and risk factor disclosures referenced in its news releases.

Frequently Asked Questions about Xebra Brands Ltd. (XBRAF)

• What does Xebra Brands Ltd. do?
  

  Xebra Brands Ltd. describes itself as a Canadian cannabis company with international reach, focused on the development and commercialization of cannabis‑derived wellness and consumer products. It also refers to itself as an international cannabis cultivation and product company with global brands and intellectual property, with a focus on beverages, wellness and leisure.

• In which markets does Xebra operate?
  

  According to its public disclosures, Xebra operates in Mexico, Canada and the United States. It has received authorization from COFEPRIS in Mexico to import, cultivate, manufacture and sell cannabis with less than 1% THC, retails Vicious Citrus THC/CBN lemonades in Canada, and is working to commercialize its ELEMENTS™ CBD product line in the U.S. through manufacturing and distribution partnerships.

• What is the ELEMENTS™ product line?
  

  Xebra describes ELEMENTS™ as a CBD product line that includes branded tinctures, gummies, topicals and wellness supplements. The company has reported that it is advancing the U.S. launch of ELEMENTS™ through a manufacturing and distribution agreement with NF Skin and integration into RT Fulfillment’s logistics and e‑commerce infrastructure.

• What role does Mexico play in Xebra’s business?
  

  Mexico is a key jurisdiction for Xebra. The company states that it is an absolute first mover in the Mexican cannabis sector, with the first authorization granted by COFEPRIS to a corporation to import, cultivate, manufacture and sell cannabis with less than 1% THC. Xebra refers to its operations in Mexico as federally licensed and central to its cannabis‑derived product strategy.

• On which exchanges does Xebra Brands trade?
  

  In its news releases, Xebra reports that its shares trade on the Canadian Securities Exchange under the symbol XBRA, on the OTC market in the United States under XBRAF, and on the Frankfurt Stock Exchange under symbols such as 9YC or 9YC0, depending on the specific disclosure.

• What is the status of Xebra’s financial statement filings?
  

  Xebra has disclosed delays in filing its audited annual financial statements, management’s discussion and analysis and related officer certifications for the fiscal year ended February 28, 2025, as well as certain interim financial statements. These delays led to a management cease trade order and subsequently a failure‑to‑file cease trade order issued by the British Columbia Securities Commission, which suspends trading in its securities in applicable Canadian jurisdictions until the required documents are filed and the order is revoked.

• Has Xebra undertaken any share consolidation?
  

  The company has announced a consolidation of its issued and outstanding common shares on the basis of ten pre‑consolidation shares for one post‑consolidation share, subject to regulatory approvals and the status of the CTO. Xebra has explained that no fractional shares will be issued and that fractional interests will be rounded up or down according to specified thresholds. It has also indicated that its outstanding warrants and options will be adjusted on the same basis.

• What products does Xebra mention in Canada?
  

  In its corporate updates, Xebra states that in Canada it retails Vicious Citrus THC/CBN lemonades. These beverages are identified as part of its focus on cannabis‑derived products in the beverages, wellness and leisure categories.

• How is Xebra expanding in the United States?
  

  Xebra reports that it is advancing a U.S. commercialization strategy for its ELEMENTS™ CBD product line. It has entered into manufacturing and distribution agreements, including with NF Skin and RT Fulfillment, and has worked on product formulations, packaging, e‑commerce planning, compliance readiness and logistics integration to support direct‑to‑consumer fulfillment and distribution across the United States.

• What risks does Xebra highlight in its disclosures?
  

  In its forward‑looking statements, Xebra references risks such as the ability to retain regulatory authorizations, generate sufficient revenues or funding, changes in legislation and regulations, risks associated with agriculture and cultivation, compliance with import and export laws, fluctuations in cannabis prices and transportation costs, obtaining necessary licenses and permits, dependence on third parties, and general economic conditions. It also notes uncertainties related to maintaining its market position and the uniqueness of its products.